| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Powerbase Energy Systems Inc. is a Carleton Place, ON-based company in the Software and Internet sector.
dscout’s qualitative research platform uses a mobile app and +100K eager participants to efficiently capture in-the-moment video and make insights easy to…
Waypoint is an open source solution that provides a modern workflow for build, deploy, and release across platforms. Waypoint allows developers to deploy, manage, and observe their applications through a consistent abstraction of underlying infrastruct...
A recognized innovator in transaction services, we focus on offering the flexibility and control required to respond rapidly to market demands.